{
  "payload": {
    "molecule": "Pamrevlumab",
    "recommendation": "Go",
    "market_score": 82,
    "innovation_story": "Pamrevlumab combines statistically meaningful FVC preservation with biomarker-driven patient selection in PF-ILD, and partner-ready manufacturing plus orphan pricing elevate it to a Go call.",
    "workers": {
      "clinical": {
        "summary": "Phase 3 ZEPHYRUS-1 hit its primary with 128 mL FVC benefit and clean safety profile.",
        "confidence": 0.81,
        "confidence_band": "high",
        "evidence": [
          {
            "type": "Trial",
            "text": "Pamrevlumab arm lost 260 mL vs 388 mL placebo over 48 weeks (p=0.01).",
            "url": "https://clinicaltrials.gov/study/NCT03955146",
            "confidence": 0.83
          },
          {
            "type": "Trial",
            "text": "Open-label extension maintained lung function with no new safety findings.",
            "url": "https://example.org/trial/ole",
            "confidence": 0.74
          }
        ]
      },
      "literature": {
        "summary": "Multiple journals confirm CTGF inhibition reduces fibroblast proliferation and collagen deposition in PF-ILD models.",
        "confidence": 0.77,
        "confidence_band": "high",
        "evidence": [
          {
            "type": "Mechanism",
            "text": "CTGF neutralization cut hydroxyproline content by 37% in bleomycin mice.",
            "url": "https://pubmed.ncbi.nlm.nih.gov/35111290/",
            "confidence": 0.75
          }
        ]
      },
      "market": {
        "summary": "Premium orphan pricing with 45k PF-ILD patients and limited head-to-head competition drives >$1.6B TAM.",
        "confidence": 0.72,
        "confidence_band": "high",
        "evidence": [
          {
            "type": "Market",
            "text": "KOL panel expects 35% adoption within 3 years given combination potential with nintedanib.",
            "url": "https://example.org/market/pamrevlumab",
            "confidence": 0.7
          }
        ]
      }
    },
    "quality": {
      "status": "pass",
      "alerts": {}
    }
  }
}
